16 : 14 Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC et al
Inicialmente, se comercializaron monoagonistas de GLP-1R que tuvieron como objetivo el tratamiento de la diabetes tipo2, explotando el efecto incretnico y su carcter glucosa-dependiente, a lo que se aadi la accin reductora del peso corporal y sus efectos sobre comorbilidades asociadas1,3,5
Phase 2 data published in 2023 demonstrated average weight loss of 24.2% at the highest dose, surpassing both Tirzepatide and Semaglutide
These peptides are not magic solutions but rather tools that may support the body's natural healing and recovery processes when used appropriately
Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation
This is the essence of their "divergent expression"they boost your brain in different ways